"Denosumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A humanized monoclonal antibody and an inhibitor of the RANK LIGAND, which regulates OSTEOCLAST differentiation and bone remodeling. It is used as a BONE DENSITY CONSERVATION AGENT in the treatment of OSTEOPOROSIS.
| Descriptor ID |
D000069448
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.782 D12.776.124.790.651.114.224.060.782 D12.776.377.715.548.114.224.200.782
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Denosumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Denosumab [D12.776.124.486.485.114.224.060.782]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Denosumab [D12.776.124.790.651.114.224.060.782]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Denosumab [D12.776.377.715.548.114.224.200.782]
Below are MeSH descriptors whose meaning is more specific than "Denosumab".
This graph shows the total number of publications written about "Denosumab" by people in this website by year, and whether "Denosumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 1 | 2 |
| 2017 | 7 | 6 | 13 |
| 2018 | 6 | 0 | 6 |
| 2019 | 3 | 1 | 4 |
| 2020 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Denosumab" by people in Profiles.
-
Adherence to dosing schedule of denosumab therapy for osteoporosis during COVID-19 lockdown: an electronic medical record and pharmacy claims database study from Asia. Osteoporos Int. 2022 Jan; 33(1):251-261.
-
Osteoporosis Management Strategies in the COVID-19 Pandemic. South Med J. 2020 12; 113(12):612-613.
-
Controversies in the use of new bone-modifying therapies in multiple myeloma. Br J Haematol. 2021 Jun; 193(6):1034-1043.
-
Are women with osteoporosis treated with denosumab at risk of severe COVID-19? Endocrine. 2020 11; 70(2):203-205.
-
Osteoporosis Management in the Era of COVID-19. J Bone Miner Res. 2020 06; 35(6):1009-1013.
-
Osteoporosis in the age of COVID-19. Osteoporos Int. 2020 Jul; 31(7):1189-1191.
-
Denosumab effects on serum levels of the bone morphogenetic proteins antagonist noggin in patients with transfusion-dependent thalassemia and osteoporosis. Hematology. 2019 Dec; 24(1):318-324.
-
Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ. 2020 Jan; 23(1):37-47.
-
Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody. Cancer Treat Rev. 2019 Jun; 76:57-67.
-
Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review. Singapore Med J. 2019 Jul; 60(7):364-378.